10X GENOMICS ($TXG) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.10 per share, beating estimates of -$0.29 by $0.19. The company also reported revenue of $150,840,000, beating estimates of $147,818,883 by $3,021,117.
Stock price change since market close: -2.19%
You can see Quiver Quantitative's $TXG stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
10X GENOMICS Insider Trading Activity
10X GENOMICS insiders have traded $TXG stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:
- SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 7 sales selling 59,045 shares for an estimated $1,209,653.
- ADAM TAICH (Chief Financial Officer) has made 0 purchases and 2 sales selling 20,856 shares for an estimated $392,444.
- BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 16,109 shares for an estimated $302,741.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
10X GENOMICS Hedge Fund Activity
We have seen 154 institutional investors add shares of 10X GENOMICS stock to their portfolio, and 174 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 4,195,603 shares (-77.2%) from their portfolio in Q4 2025, for an estimated $68,430,284
- FMR LLC added 3,459,481 shares (+40.9%) to their portfolio in Q4 2025, for an estimated $56,424,135
- WELLINGTON MANAGEMENT GROUP LLP removed 2,836,863 shares (-66.2%) from their portfolio in Q4 2025, for an estimated $46,269,235
- BANK OF AMERICA CORP /DE/ removed 1,575,766 shares (-46.2%) from their portfolio in Q4 2025, for an estimated $25,700,743
- CASDIN CAPITAL, LLC added 1,400,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $22,834,000
- ROYAL BANK OF CANADA removed 1,321,614 shares (-92.4%) from their portfolio in Q4 2025, for an estimated $21,555,524
- QUANTINNO CAPITAL MANAGEMENT LP added 1,174,744 shares (+33.6%) to their portfolio in Q4 2025, for an estimated $19,160,074
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
10X GENOMICS Government Contracts
We have seen $8,843,695 of award payments to $TXG over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $371,793
- GENE EXPRESSION REAGENTS: $334,142
- BIOLOGICAL REAGENT MATERIAL - CHROMIUM NEXT GEM SINGLE CELL MULTIOME AND GEM-X SINGLE CELL 5 KITS AND RELAT...: $249,991
- REAGENTS FOR ONGOING NGS PROJECTS (AMBIS 2270566): $249,963
- IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - KITS AND REAGENTS USED IN SINGLE-CELL AND GENE PANEL ANALYSES: $249,934
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
10X GENOMICS Analyst Ratings
Wall Street analysts have issued reports on $TXG in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 03/31/2026
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
To track analyst ratings and price targets for 10X GENOMICS, check out Quiver Quantitative's $TXG forecast page.
10X GENOMICS Price Targets
Multiple analysts have issued price targets for $TXG recently. We have seen 10 analysts offer price targets for $TXG in the last 6 months, with a median target of $22.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $32.0 on 04/20/2026
- Derik De Bruin from B of A Securities set a target price of $30.0 on 04/20/2026
- Luke Sergott from Barclays set a target price of $30.0 on 04/14/2026
- Patrick Donnelly from Citigroup set a target price of $24.0 on 04/07/2026
- Daniel Arias from Stifel set a target price of $25.0 on 03/02/2026
- Dan Leonard from UBS set a target price of $20.0 on 02/20/2026
- Dan Brennan from TD Cowen set a target price of $19.0 on 02/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
